Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance.
biomarkers
gynecologic oncology
translational research
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
16
11
2018
revised:
05
12
2018
accepted:
06
12
2018
pubmed:
15
2
2019
medline:
21
5
2020
entrez:
15
2
2019
Statut:
ppublish
Résumé
Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA-125 and sFR.
Identifiants
pubmed: 30761774
doi: 10.1002/cam4.1944
pmc: PMC6434204
doi:
Substances chimiques
Biomarkers, Tumor
0
CA-125 Antigen
0
FOLR1 protein, human
0
Folate Receptor 1
0
MUC16 protein, human
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-927Subventions
Organisme : NCI NIH HHS
ID : R21 CA187278
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Clin Biochem. 2013 Oct;46(15):1462-8
pubmed: 23528302
Cancer Biomark. 2012;11(2-3):59-73
pubmed: 23011153
Annu Rev Nutr. 1996;16:501-21
pubmed: 8839936
J Biol Chem. 1996 May 10;271(19):11493-9
pubmed: 8626708
Int J Gynecol Cancer. 2016 Nov;26(9):1586-1593
pubmed: 27540691
Cancer Biomark. 2010-2011;8(4-5):161-6
pubmed: 22045350
Cancer Res. 2005 May 15;65(10):4431-41
pubmed: 15899836
Sci Transl Med. 2011 Nov 16;3(109):109ra116
pubmed: 22089452
J Clin Pathol. 2013 Apr;66(4):273-81
pubmed: 23426716
J Ovarian Res. 2013 Apr 17;6(1):29
pubmed: 23590973
Gynecol Oncol Rep. 2017 Jun 15;21:37-44
pubmed: 28653032
Open Biol. 2017 Feb;7(2):
pubmed: 28202626
Gynecol Oncol. 2015 Feb;136(2):205-11
pubmed: 25546113
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1333-40
pubmed: 27448593
Biochemistry. 1995 Apr 25;34(16):5660-5
pubmed: 7727426
Br J Cancer. 2014 Dec 9;111(12):2297-307
pubmed: 25349970
Int J Cancer. 2016 Apr 15;138(8):1994-2002
pubmed: 26595060
Womens Health (Lond). 2014 Sep;10(5):519-33
pubmed: 25335543
Prz Menopauzalny. 2015 Dec;14(4):254-9
pubmed: 26848298
Cancer Med. 2019 Mar;8(3):920-927
pubmed: 30761774
PLoS One. 2009 Jul 20;4(7):e6292
pubmed: 19617914
Curr Opin Obstet Gynecol. 2014 Feb;26(1):3-8
pubmed: 24247932
Oncology (Williston Park). 2013 Apr;27(4):288-94, 298
pubmed: 23781692
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Mol Biol. 1999 Mar 12;286(5):1303-10
pubmed: 10064698